Photodynamic therapy in nonsmall cell lung cancer: a systematic review

Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo

“…25,26 NSCLC represents approximately 80% of all types of lung cancer and includes adenocarcinomas, large-cell carcinomas and squamous cell carcinomas. 27,28 Therefore, the exploration and development of new and effective phytochemicals that are non-toxic in nature and that can target the molecules associated with epigenetic regulators could lead to substantially improved outcomes in patients with this type of cancer.…”

Autofluorescence bronchoscopy: Clinical experience with an optimized system in head and neck cancer patients

“…Early detection and treatment of these second primaries can significantly improve the patient 5-year survival rate. While the 5-year survival rate is about 15% [19,20] for bronchial cancer patients non-undergoing treatment, it increases to about 80% for patients with early stage cancer undergoing treatment (surgery, cryotherapy or PDT) when the cancer is still in an early stage [21].…”

A look at clinical applications and developments of photodynamic therapy

“…Recently Maziak et al [25], published a different point of view stating that there is insufficient high-quality evidence on which to base guidelines for the treatment of nonsmall cell lung cancer and that this treatment modality can be considered only for palliation. Palliation is necessary in order to maintain the airway and consequent life quality of the patients.…”